Sepúlveda-Crespo, DanielYélamos López, María BelénDíez, CristinaGómez Gutiérrez, JuliánHontañón, VíctorTorresano Felipe, FranciscoBerenguer, JuanGonzález García, JuanIbañez-Samaniego, LuisLlop, ElvaOlveira, AntonioMartínez, JavierResino, SalvadorMartínez, Isidoro2026-04-162026-04-162022-04-25Daniel Sepúlveda-Crespo, María Belén Yélamos, Cristina Díez, Julián Gómez, Víctor Hontañón, Francisco Torresano-Felipe, Juan Berenguer, Juan González-García, Luis Ibañez-Samaniego, Elva Llop, Antonio Olveira, Javier Martínez, Salvador Resino, Isidoro Martínez, Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis, Biomedicine & Pharmacotherapy, Volume 150, 2022, 1130240753-332210.1016/j.biopha.2022.113024https://hdl.handle.net/20.500.14352/134815Objectives The current study aimed to assess the impact of HIV on the production of anti-HCV antibodies in HCV-infected individuals with advanced HCV-related cirrhosis before and 36 weeks after the sustained virological response (SVR) induced by direct-acting antivirals (DAAs) therapy. Methods Prospective study on 62 patients (50 HIV/HCV-coinfected and 12 HCV-monoinfected). Plasma anti-E2 and HCV-nAbs were determined respectively by ELISA and microneutralization assays. Results At baseline, the HCV-group had higher anti-E2 levels against Gt1a (p = 0.012), Gt1b (p = 0.023), and Gt4a (p = 0.005) than the HIV/HCV-group. After SVR, anti-E2 titers against Gt1a (p < 0.001), Gt1b (p = 0.001), and Gt4a (p = 0.042) were also higher in the HCV-group than HIV/HCV-group. At 36 weeks post-SVR, plasma anti-E2 titers decreased between 1.3 and 1.9-fold in the HIV/HCV-group (p < 0.001) and between 1.5 and 1.8-fold in the HCV-group (p ≤ 0.001). At baseline, the HCV-group had higher titers of HCV-nAbs against Gt1a (p = 0.022), Gt1b (p = 0.002), Gt2a (p < 0.001), and Gt4a (p < 0.001) than the HIV/HCV-group. After SVR, HCV-nAbs titers against Gt1a (p = 0.014), Gt1b (p < 0.001), Gt2a (p = 0.002), and Gt4a (p = 0.004) were also higher in the HCV-group. At 36 weeks post-SVR, HCV-nAbs decreased between 2.6 and 4.1-fold in the HIV/HCV-group (p < 0.001) and between 1.9 and 4.0-fold in the HCV-group (p ≤ 0.001). Conclusions HIV/HCV-coinfected patients produced lower levels of broad-spectrum anti-HCV antibodies than HCV-monoinfected patients.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/journal articlehttps://doi.org/10.1016/j.biopha.2022.113024https://www.sciencedirect.com/science/article/pii/S0753332222004139?via%3Dihubopen access66.0Hepatitis CHIVHIV/HCV coinfectionBroad-spectrum neutralizing antibodiesDirect-acting antiviralsHCV clearanceBioquímica (Medicina)Bioquímica (Química)2302 Bioquímica2412 Inmunología2420 Virología